Using CRISPR to change fat cells to improve blood sugar control in obesity and diabetes
CRISPR-enhanced adipocyte browning to improve glucose tolerance in obesity and diabetes
['FUNDING_R01'] · UNIV OF MASSACHUSETTS MED SCH WORCESTER · NIH-10878904
This study is exploring a way to change regular fat cells in our bodies into a type of fat that burns energy better, which could help people with obesity and diabetes manage their health more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MASSACHUSETTS MED SCH WORCESTER (nih funded) |
| Locations | 1 site (WORCESTER, UNITED STATES) |
| Trial ID | NIH-10878904 on ClinicalTrials.gov |
What this research studies
This research aims to genetically modify human white fat cells to take on characteristics of brown fat cells, which are better at burning energy and improving metabolic health. The approach uses a CRISPR-based technology that delivers gene-editing tools directly to fat cell precursors without the use of viruses, ensuring high efficiency. By targeting specific genes that suppress the 'browning' of fat, the researchers hope to create a new type of fat cell that can help manage obesity and diabetes more effectively. The ultimate goal is to test these modified cells in animal models to assess their impact on glucose tolerance and overall metabolic health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from obesity and type 2 diabetes who may benefit from improved metabolic health.
Not a fit: Patients who do not have obesity or diabetes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for obesity and diabetes by enhancing the body's ability to regulate blood sugar levels.
How similar studies have performed: Other research has shown promising results with CRISPR technology in modifying fat cells, indicating potential for success in this novel approach.
Where this research is happening
WORCESTER, UNITED STATES
- UNIV OF MASSACHUSETTS MED SCH WORCESTER — WORCESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CZECH, MICHAEL P — UNIV OF MASSACHUSETTS MED SCH WORCESTER
- Study coordinator: CZECH, MICHAEL P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus